- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00940836
Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome
Phase III Clinical Trial - Efficacy and Safety Assessment of a Compound Acetaminophen, Chlorpheniramine and Phenylephrine Combination in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome in Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Upper respiratory infections are rather frequent in the population, and their treatment consists, in most cases, in the use of symptomatic drugs. Acetaminophen is widely used as an analgesic and antipyretic, whereas chlorpheniramine is an antihistaminic and phenylephrine is a vasoconstrictor with decongestioning activity. The aim of this study is to assess the efficacy and safety of an anti-cold preparation, currently commercialized in Brazil by the name Resfenol, compounded by acetaminophen, chlorpheniramine and phenylephrine for the treatment of cold and flu symptoms in healthy individuals in a randomized, double-blind, placebo-controlled clinical trial.
Healthy volunteers are recruited through panels fixated at Hospital de Clínicas de Porto Alegre, in Brazil, and must answer a screening questionnaire at first contact. One hundred and forty six patients who met the inclusion criteria were included and, after baseline clinical and laboratory evaluation, were randomized to receive either the active intervention or placebo, 5 times a day, at 4 hour intervals, during 48 to 72 hours, depending on patient availability to show up for re-evaluation. Patients also received acetaminophen as a co intervention, to be taken only in case of persisting symptoms.
Patients answered, during treatment, several symptom questionnaires contained in a diary, and followup was performed at days 3 or 4 (clinical and laboratory evaluation) and 10 or 11 (clinical followup). Axillary temperature was assessed along with every dose with a thermometer provided by the study and registered in the diary.
Primary endpoint consists in the mean symptom scores, assessed through questionnaires in patient diary, baseline and followup. Secondary endpoints are global duration of symptoms, time of return to usual activities, use of co intervention for symptom relief, improval of fever and adverse effect evaluation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Paulo D Picon, MD, PhD
- Phone Number: 55 xx 51 33598752
- Email: paulopicon@gmail.com
Study Locations
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
- Recruiting
- Hospital de Clínicas de Porto Alegre
-
Principal Investigator:
- Paulo D Picon, MD, PhD
-
Sub-Investigator:
- Indara C Saccilotto, Administration
-
Sub-Investigator:
- Jorge A Szymanski, Medicine
-
Sub-Investigator:
- Marisa B Costa, Pharmacy
-
Sub-Investigator:
- Lúcia C Fendt, Med Student
-
Sub-Investigator:
- Mauricio L Suksteris, Med Student
-
Sub-Investigator:
- Alicia D Dornelles, Med Student
-
Sub-Investigator:
- Carolina R Barone, Med Student
-
Sub-Investigator:
- Loise P Smaniotto, Med Student
-
Sub-Investigator:
- Juliana Azambuja, Med Student
-
Sub-Investigator:
- Juliana F Zampieri, Med Student
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 to 60 years old;
- Presenting with at least 6 and at max 72 hours of common cold symptoms (headache, muscle ache, rhinorrhea, nasal obstruction, sneezing, cough, sore or irritated throat, hoarseness, fever) or flu-like syndrome (high fever, muscle or articular ache, headache), with at least two symptoms rated by the patient as moderated to severe in an 0 to 4 scale;
- Proper anticonception, in the case of women in fertile age;
- Possibility to abstain from using any other drug for the treatment of the studied condition, except in emergencies, in wich case the responsible party must be immediately notified;
- Cooperation and understanding skills;
- Agreement to informed consent form.
Exclusion Criteria:
- Pregnant or lactating women;
- Hypersensitivity to any of the drug's components;
- Alcohol or substance abuse;
- Use of MAO inhibitor or barbituric;
- Diagnosis of any acute disease in current activity or uncontrolled chronic disease;
- Clinical evidence of immunosuppression;
- Influenza vaccine less than a week prior to inclusion;
- Need for antibiotic treatment for the respiratory infection, in the opinion of the investigator;
- Having participated in other clinical trial less than one year prior to inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Resfenol
Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation. Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day. |
Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine.
Patients will receive up to five capsules a day.
Other Names:
All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Other Names:
|
Placebo Comparator: Placebo
Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator. Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day. |
All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
Other Names:
Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Symptom improval assessed by questionnaires concerning headache, muscle ache, rhinorrhea, nasal obstruction, sneezes, cough, sore or irritated throat, hoarseness and fever, rated by patient himself in a scale from 0 to 4, being 0-absence and 4-severe.
Time Frame: Questionnaires were answered at baseline and 1st followup to the investigator and during treatment at every dose, 5 times a day, from day 1 to 3/4, through patient's diary.
|
Questionnaires were answered at baseline and 1st followup to the investigator and during treatment at every dose, 5 times a day, from day 1 to 3/4, through patient's diary.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global duration of symptoms, assessed by the investigator through direct questioning at followup visits.
Time Frame: Day 3/4 and, if no relief yet, day 10/11.
|
Day 3/4 and, if no relief yet, day 10/11.
|
Time of return to usual activities, such as work or gym, assessed by the investigator through direct questioning at followup visits.
Time Frame: Day 3/4 and, if no relief yet, day 10/11.
|
Day 3/4 and, if no relief yet, day 10/11.
|
Use of co intervention for symptom relief during treatment, registered by the volunteer in patient diary, with day and hour of ingestion.
Time Frame: Assessed during treatment (day 1 to 3/4) by patient diary and questioned by investigator at 1st followup visit.
|
Assessed during treatment (day 1 to 3/4) by patient diary and questioned by investigator at 1st followup visit.
|
Improval of fever by reduction of axillary temperature to less than 38,1°C.
Time Frame: Assessed by investigator at baseline and 1st followup visit and by patient (with termometer provided by the study) along with every dose, 5 times a day, from day 1 to 3/4, registered in patient diary.
|
Assessed by investigator at baseline and 1st followup visit and by patient (with termometer provided by the study) along with every dose, 5 times a day, from day 1 to 3/4, registered in patient diary.
|
Adverse effect appearance during and until 7 days after treatment, assessed through patient's report in the diary or followup visit, through physical evaluation at followup and by laboratory exams.
Time Frame: Days 1 to 3/4 through patient diary, and followup at days 3/4 an 10/11.
|
Days 1 to 3/4 through patient diary, and followup at days 3/4 an 10/11.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Disease
- Picornaviridae Infections
- Syndrome
- Common Cold
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Dermatologic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Acetaminophen
- Chlorpheniramine
- Phenylephrine
Other Study ID Numbers
- 05492
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Common Cold
-
Cardiff UniversityCompletedCommon Cold/FluUnited Kingdom
-
Perrigo CompanyGlaxoSmithKline; Pfizer; McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. and other collaboratorsCompletedNasal Congestion Associated With the Common ColdUnited States
-
NovartisCompletedCommon Cold Associated With CoughCanada
-
Probi ABCompletedAcute Upper Respiratory Tract Infections (Common Cold)Italy
-
Ache Laboratorios Farmaceuticos S.A.Suspended
-
Beijing Da-an Bio-technology Co., Ltd.Unknown
-
Brainfarma Industria Química e Farmacêutica S/ATechtrials Pesquisa e Tecnologia Ltda; PharmagenixUnknown
-
NovartisCompletedSore Throat Due to a Common ColdGermany
-
Boehringer IngelheimCompleted
-
Lund UniversityCoradil ABEnrolling by invitation
Clinical Trials on Resfenol
-
Hospital de Clinicas de Porto AlegreCompletedInfluenza | Common ColdBrazil
-
Brainfarma Industria Química e Farmacêutica S/ATechtrials Pesquisa e Tecnologia Ltda; PharmagenixUnknown